Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche receives FDA Approval for novel PD-L1 biomarker assay

The VENTANA PD-L1 (SP142) Assay was approved as a complementary diagnostic for Tecentriq immunotherapy.

Read More »

Zika virus may spread to Europe in coming months, WHO warns

The Zika virus may spread into Europe as the weather gets warmer, although the risk is low, health officials said.

Read More »

Oramed says oral insulin succeeds in midstage type 2 diabetes trial

Oramed Pharmaceuticals’ experimental oral insulin succeeded in significantly reducing night-time blood glucose in a midstage trial.

Read More »

Novartis AG’s Pharma Head Exits as Drug Business is Split into Two

Novartis split its pharmaceuticals division into two separate business units focused on drug development and cancer.

Read More »

MacroGenics Wrangles Cancer Deal Worth $755 Million Out of Janssen Biotech

MacroGenics Enters Collaboration and License Agreement with Janssen to Develop New DART Molecule for the Treatment of Cancer.

Read More »

Agios, Celgene Hammer Out $1 Billion+ Metabolic Immuno-Oncology Deal

Cambridge, Massachusetts-based Agios Pharmaceuticals inked a new global collaboration deal with Summit, New Jersey-based Celgene.

Read More »

Novartis breast cancer drug set to take on Pfizer’s Ibrance

A clinical trial testing an experimental breast cancer pill from Novartis has been stopped early because of good results, boosting the Swiss company’s efforts to build up its oncology business.

Read More »

AstraZeneca’s Lynparza fails in gastric cancer combination test

AstraZeneca’s recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said .

Read More »

Coherus says USPTO to review AbbVie’s Humira

Coherus BioSciences said the U.S. Patent and Trademark office agreed to review its petition to make a copy of AbbVie’s top-selling arthritis drug Humira.

Read More »

Relypsa Falls on Unimpressive Veltassa Script Data

Redwood City, California-based Relypsa disclosed prescription sales information for Veltassa that led to a stock decline of 7.8 percent.

Read More »

Catalyst Pharma Axes 30% of Workforce

Catalyst Pharmaceuticals is slashing its workforce by about 30 percent in an effort to conserve capital and save its investigational drug program for the treatment of LEMS and CMS.

Read More »

AstraZeneca asthma drug hits goal, to enter competitive market

AstraZeneca’s drive to rebuild its portfolio of new medicines received a boost with positive results for an experimental biotech drug for severe asthma that the company previously flagged as a potential $2 billion-a-year seller.

Read More »

Pfizer’s Anacor deal showcases new wave of eczema therapies

Pfizer Inc’s purchase of Anacor Pharmaceuticals Inc heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema, a common skin condition that causes infection-prone rashes that can feel like having poison ivy 24 hours a day.

Read More »

Meeting current and future serialization challenges

A white paper from Aesica, a leading pharmaceutical contract development and manufacturing organization (CDMO) for both APIs and finished dosage forms.   Serialization has emerged as a complex challenge for the pharmaceuticals sector,, which is facing a multiplicity of differing regulations that vary from one country to another. Several countries including China, South Korea, Turkey, […]

Read More »

Career Conversation 11 – Conflict Management (HBA)

Webinar: Career Conversation 11 – Conflict Management Tue, Jun 7, 2016 12:00 PM – 1:15 PM How do you keep your professional “cool” when conversing with an irrational person? Join us for the 11th program in the Career Conversations webinar series to learn how.       Event Time Zone: Eastern Time Event Type: Program […]

Read More »

Obama administration releases rules on wellness programs

A federal agency released final rules on how employers can offer workers financial incentives of up to 30 percent of the cost of their cheapest health insurance plans to participate in wellness programs without violating federal laws protecting the confidentiality of medical information.

Read More »

U.S. House to weigh $622.1 million in new Zika funding

Republicans in the U.S. House of Representatives will try to pass legislation this week providing $622.1 million in funds to fight the spreading Zika virus, far less than the Obama administration has been seeking.

Read More »

Omnicom Public Relations Group Acquires Rabin Martin

Omnicom Public Relations Group, part of Omnicom Group Inc. (NYSE: OMC), today announced the acquisition of Rabin Martin, an innovative global health strategy consulting firm.

Read More »

Valeant to increase hospital discounts for two heart drugs

Valeant will raise the discounts to hospitals on its heart drugs Nitropress and Isuprel to as much as 40 percent off list prices.

Read More »

Faced with shortages, Egypt lifts cheap drug prices by 20 percent

Egypt is raising the price cap on medicines that cost up to 30 Egyptian pounds ($3.38) by 20 percent in an effort to address drug shortages, the health minister said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom